Valneva (NASDAQ:VALN) Rating Lowered to Hold at Zacks Investment Research

Zacks Investment Research cut shares of Valneva (NASDAQ:VALN) from a strong-buy rating to a hold rating in a research report sent to investors on Wednesday, Zacks.com reports.

According to Zacks, “Valneva SE is a specialty vaccine company. It is focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. Valneva SE is based in Saint-Herblain, France. “

A number of other research analysts have also recently weighed in on VALN. UBS Group cut shares of Valneva from a neutral rating to a sell rating in a research note on Wednesday, December 22nd. Jefferies Financial Group started coverage on shares of Valneva in a research note on Friday, September 24th. They set a buy rating and a $39.00 price objective for the company. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of Hold and a consensus price target of $41.25.

Shares of Valneva stock opened at $37.44 on Wednesday. The company has a quick ratio of 0.95, a current ratio of 1.23 and a debt-to-equity ratio of 0.62. The company has a 50-day moving average of $50.75 and a two-hundred day moving average of $39.47. Valneva has a 12-month low of $24.16 and a 12-month high of $67.84.

A number of hedge funds and other institutional investors have recently made changes to their positions in VALN. CVI Holdings LLC acquired a new stake in Valneva during the second quarter worth approximately $1,486,000. Laurion Capital Management LP acquired a new stake in Valneva during the second quarter worth approximately $659,000. Tudor Investment Corp Et Al acquired a new stake in Valneva during the second quarter worth approximately $203,000. Citadel Advisors LLC acquired a new stake in Valneva during the second quarter worth approximately $5,138,000. Finally, Millennium Management LLC acquired a new stake in Valneva during the second quarter worth approximately $259,000. Hedge funds and other institutional investors own 0.50% of the company’s stock.

About Valneva

Valneva SE, a specialty vaccine company, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; and DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium.

Read More: What is the S&P 500 Index?

Get a free copy of the Zacks research report on Valneva (VALN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Valneva (NASDAQ:VALN)

Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with MarketBeat.com's FREE daily email newsletter.